PulmoCheck+
Investigate 3,000+ genes for precise diagnosis of hereditary pulmonary diseases, aiding tailored treatments, prevention, and family planning.
Simple Buccal Swab-FDA
Our panels consist of more than 3,000 genes that have been carefully chosen using curated gene reviews, variant databases (HGMD and ClinVar), the latest research, and input from our customers. We provide highly effective clinical utility, maximum diagnostic yield, and the ability to make differential diagnoses. Our panels contain up-to-date, analytically validated genes, including those that are difficult to sequence, ensuring accurate diagnoses in even the most challenging patient cases.
Pulmonary diseases have high genetic heterogeneity with significant phenotypic overlap. Given the many genes and mutations underlying hereditary pulmonary diseases, NGS and multi-gene panels are often cost-effective primary options for genetic diagnostics.
Genetic diagnostics are usually the best and fastest method when identifying hereditary pulmonary diseases. These tests give doctors the information they need to make informed decisions about treatment and management tailored to each patient’s needs. Specifically, variation in the CFTR gene that causes cystic fibrosis is targeted in this category. Screening enables targeted, genotype-specific therapies to improve CFTR function, as recommended by a recent publication (PMID: 26403534). In addition to cystic fibrosis, determining the underlying genetic defect in any hereditary pulmonary disease affects genetic counseling and risk assessment.
Genetic testing has proven helpful in identifying hereditary pulmonary diseases, such as primary ciliary dyskinesia (PCD). PCD is a genetic disorder that affects the function of motile cilia. Clinically, PCD may present with neonatal respiratory distress, chronic coughing, and recurrent sinus or ear infections. In 15–50% of PCD cases, some or even all major visceral organs are reversed from their regular positions – the partial form called situs ambiguous/heterotaxy and the complete form situs inversus. Genetic diagnosis helps understand a patient’s symptomology, and testing will differentiate it from cystic fibrosis, which may mimic the clinical presentation of PCD.
Identifying at-risk family members makes it possible to begin preventive treatments and make lifestyle recommendations. It also justifies routine follow-ups by healthcare professionals. Genetic diagnostics can help in family planning.
The Pulmonary Panel is designed to detect single nucleotide variants (SNVs) and small insertions and deletions in 63genes associated with neurological risk. Targeted regions for this panel include the coding exons and 10 bp intronic sequencesimmediate to the exon-intron boundary of each coding exon in each of these genes. Extracted patient DNA is prepared using targetedhybrid capture, assignment of a unique index, and sequencing via Illumina sequencing by synthesis (SBS) technology. Data is alignedusing human genome build GRCh37. Variant interpretation is performed according to current American College of Medical Geneticsand Genomics (ACMG) professional guidelines for the interpretation of germline sequence variants using Fabric EnterpriseTM Pipeline6.6.15. Variant interpretation and reporting is performed by Fabric Clinical (CLIA ID: 45D2281059 and CAP ID: 9619501). The followingquality filters are applied to all variants: quality <500, allelic balance <0.3, coverage <10x.
This test aims to detect all clinically relevant variants within the coding regions of the genes evaluated. Pathogenic and likelypathogenic variants detected in these genes should be confirmed by orthogonal methods. Detected genetic variants classified asbenign, likely benign, or of uncertain significance are not included in this report. Homopolymer regions and regions outside of thecoding regions cannot be captured by the standard NGS target enrichment protocols. At this time, the assay does not detect largedeletions and duplications. This analysis also cannot detect pathogenic variants within regions which were not analyzed (e.g., introns,promoter and enhancer regions, long repeat regions, and mitochondrial sequence). This assay is not designed to detect mosaicismand is not designed to detect complex gene rearrangements or genomic aneuploidy events. It is important to understand that theremay be variants in these genes undetectable using current technology. Additionally, there may be genes associated with neurologicalpathology whose clinical association has not yet been definitively established. The test may therefore not detect all variantsassociated with neurological pathology. The interpretation of variants is based on our current understanding of the genes in this paneland is based on current ACMG professional guidelines for the interpretation of germline sequence variants. Interpretations maychange over time as more information about the genes in this panel becomes available. Qualified health care providers should beaware that future reclassifications of genetic variants can occur as ACMG guidelines are updated. Factors influencing the quantityand quality of extracted DNA include, but are not limited to, collection technique, the amount of buccal epithelial cells obtained, thepatient’s oral hygiene, and the presence of dietary or microbial sources of nucleic acids and nucleases, as well as other interferingsubstances and matrix-dependent influences. PCR inhibitors, extraneous DNA, and nucleic acid degrading enzymes may adversely affect assay results.
This laboratory developed test (LDT) was developed and its performance characteristics were determined by PreCheck HealthServices, Inc. This test was performed at PreCheck Health Services, Inc. (CLIA ID: 10D2210020 and CAP ID: 9101993) that is certifiedunder the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity testing. This assayhas not been cleared or approved by the U.S. Food and Drug Administration (FDA). Clearance or approval by the FDA is not requiredfor the clinical use of this analytically and clinically validated laboratory developed test. This assay has been developed for clinicalpurposes and it should not be regarded as investigational or for research.
latest announcements and stay updated on our most recent developments.
.svg)
